VEGF Trap in Treating Patients With Metastatic Breast Cancer
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- National Cancer Institute (NCI)
- Study ID
- NCT00369655
- Phase
- PHASE2
- Status
- Completed
Conditions
- Metastatic Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ziv-aflibercept — BIOLOGICAL
Study Details
This phase II trial is studying how well VEGF Trap works in treating patients with metastatic breast cancer. VEGF Trap may stop the growth of tumor cells by blocking blood flow to the tumor
Key Dates
- Start date
- Jan 31, 2007
- Status verified
- Nov 2013
- Primary completion
- Mar 31, 2008
- Completion
- Jan 31, 2011
Study Design
- Enrollment
- 21 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (ziv-afibercept)Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Proportion of Patients With Confirmed Tumor Response [ Time Frame: Up to 5 years ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| North Central Cancer Treatment Group | Rochester | Minnesota | 55905 | - |
Find similar trials in Rochester, MN
By condition
By specialty
By research site
Related Studies
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerPHASE1 · Recruiting · Olema Pharmaceuticals, Inc. · Gilbert, Arizona
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerPHASE1/PHASE2 · Recruiting · Stemline Therapeutics, Inc. · Dothan, Alabama
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationPHASE3 · Recruiting · LeonaBio · Scottsdale, Arizona
- PRE-I-SPY Phase I/Ib Oncology Platform ProgramPHASE1 · Recruiting · QuantumLeap Healthcare Collaborative · Birmingham, Alabama